Home
Beam Therapeutics Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease

Beam Therapeutics Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease

Today’s Highlights October 31, 2023

Beam Therapeutics in the NEWS

Beam Therapeutics (BEAM) announced that Eli Lilly (LLY) has agreed to acquire certain rights under . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Today’s Highlights
,
October 31, 2023

Other Articles